Replimune Group Announces FDA Accelerated Approval for TUDRIQEV

What Happened
Replimune Group, Inc. announced on August 6, 2026 that the U.S. Food and Drug Administration granted accelerated approval for TUDRIQEV™ (vusolimogene oderparepvec-wtpg), previously referred to as RP1, in combination with nivolumab. The approval covers adults with unresectable advanced cutaneous melanoma who experienced disease progression on an anti–PD-1 antibody–based regimen. The company filed a press release (Exhibit 99.1) and posted a corporate presentation (Exhibit 99.2) in connection with the approval.

Key Details

• FDA granted accelerated approval on August 6, 2026 for TUDRIQEV in combination with nivolumab.
• Indication: adults with unresectable advanced cutaneous melanoma after progression on an anti–PD-1 regimen.
• Continued approval may be contingent on verification and description of clinical benefit in confirmatory trial(s).
• Replimune filed a news release and posted a corporate presentation about the approval (Exhibits 99.1 and 99.2 to the 8-K).

Why It Matters
This is a major regulatory milestone for Replimune and its oncolytic immunotherapy program: accelerated FDA approval allows the company to move toward commercial availability for a defined melanoma population. For investors, the approval can be a value catalyst, but it carries the limitations of accelerated approvals—Replimune must complete confirmatory trials to maintain the indication. Monitor upcoming commercial plans, pricing/reimbursement updates, and confirmatory trial timelines and results for their potential impact on revenue and risk.